Aratana Therapeutics Inc. (PETX)’s Financial Results Comparing With Cara Therapeutics Inc. (NASDAQ:CARA)

Aratana Therapeutics Inc. (NASDAQ:PETX) and Cara Therapeutics Inc. (NASDAQ:CARA) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aratana Therapeutics Inc. 35.41M 5.44 14.72M -0.51 0.00
Cara Therapeutics Inc. 13.47M 57.75 74.01M -1.18 0.00

Table 1 demonstrates Aratana Therapeutics Inc. and Cara Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 has Aratana Therapeutics Inc. and Cara Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Aratana Therapeutics Inc. -41.57% -23% -16.1%
Cara Therapeutics Inc. -549.44% -70.8% -50.9%

Volatility & Risk

Aratana Therapeutics Inc. has a beta of 1.38 and its 38.00% more volatile than Standard & Poor’s 500. Competitively, Cara Therapeutics Inc.’s 171.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.71 beta.


The Current Ratio and Quick Ratio of Aratana Therapeutics Inc. are 3.2 and 2.7 respectively. Its competitor Cara Therapeutics Inc.’s Current Ratio is 4.9 and its Quick Ratio is 4.9. Cara Therapeutics Inc. can pay off short and long-term obligations better than Aratana Therapeutics Inc.

Analyst Ratings

The Recommendations and Ratings for Aratana Therapeutics Inc. and Cara Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aratana Therapeutics Inc. 0 2 2 2.50
Cara Therapeutics Inc. 0 1 6 2.86

The consensus price target of Aratana Therapeutics Inc. is $6.67, with potential upside of 69.72%. Meanwhile, Cara Therapeutics Inc.’s consensus price target is $25.57, while its potential upside is 29.99%. The information presented earlier suggests that Aratana Therapeutics Inc. looks more robust than Cara Therapeutics Inc. as far as analyst view.

Institutional and Insider Ownership

Aratana Therapeutics Inc. and Cara Therapeutics Inc. has shares owned by institutional investors as follows: 69.1% and 62.5%. 2.5% are Aratana Therapeutics Inc.’s share owned by insiders. Insiders Competitively, owned 2.8% of Cara Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aratana Therapeutics Inc. -3.6% -9.26% -39.09% -23.43% 3.08% -34.42%
Cara Therapeutics Inc. -0.06% 12.33% -8.49% -14.09% 25.13% 31.77%

For the past year Aratana Therapeutics Inc. has -34.42% weaker performance while Cara Therapeutics Inc. has 31.77% stronger performance.


Aratana Therapeutics Inc. beats on 8 of the 12 factors Cara Therapeutics Inc.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the companyÂ’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The companyÂ’s lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.